Eisai Pharmaceutical - Plenty at Stake with Anti-Alzheimer R&D Programs but Lenvima Is Key
Eisai had high hopes from breast cancer treatment Halaven (eribulin) and epilepsy treatment Fycompa (perampanel). However, neither of the two has...
236 Views
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
AML represents one of the largest hematologic cancer populations with one of the worst survival rates. Global prevalence is expected to increase at...
518 Views
Japan Consensus Vs. Company Guidance - Names with a Big Disparity
With less than 4 months before the end of the fiscal year for most companies in Japan. We screened for names where there is a big disparity between...
251 Views
Lenvima (Lenvatinib) – Multiple Receptor Tyrosine Kinase (RTK) Inhibitor
In the absence of promising late stage programs that can potentially fill the revenue decline due to patent expiration of erstwhile blockbusters,...
156 Views
American Society of Hematology- (ASH) Annual Conference (2016) Review
We reviewed data presented at the American Society of Hematology (ASH) conference in San Diego last week with a focus on the evolving treatment...
356 Views